Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Red cell membrane disorders.

Patrick G Gallagher1

  • 1Department of Pediatrics, Yale University School of Medicine, 333 Cedar Street, P. O. Box 208064, New Haven, CT 06520-8064, USA. patrick.gallagher@yale.edu

Hematology. American Society of Hematology. Education Program
|November 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RPS19 and RPL5 haploinsufficient models reveal divergent ribosomal subunit controls of fetal hematopoiesis.

Nature communications·2026
Same author

Slowing the cell cycle to increase fetal hemoglobin.

Blood·2026
Same author

Neonatal Sepsis from 2014 to 2024: The Resurgence of Gram-Negative Rods.

The Journal of pediatrics·2026
Same author

Comprehensive Phenotypic and Proteomic Analyses of Human Reticulocyte Maturation.

Blood. Red cells & iron·2025
Same author

A novel isoform of tensin-1 promotes actin filament assembly for efficient erythroblast enucleation.

Blood advances·2025
Same author

Codanin-1, defective in congenital dyserythropoietic anemia I (CDA-I), regulates erythroid differentiation.

Annals of hematology·2025
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Hereditary erythrocyte membrane disorders, like hereditary spherocytosis, are diverse inherited hemolytic anemias. While splenectomy is often curative, its long-term risks necessitate careful consideration and patient-provider discussion.

Area of Science:

  • Hematology
  • Genetics
  • Internal Medicine

Background:

  • Erythrocyte membrane disorders encompass hereditary spherocytosis, elliptocytosis, pyropoikilocytosis, and stomatocytosis, presenting as inherited hemolytic anemias.
  • These conditions exhibit significant clinical, laboratory, and genetic heterogeneity, with unique mutations often found in each family with spherocytosis.

Purpose of the Study:

  • To review the current understanding of erythrocyte membrane disorders.
  • To discuss the evolving role of splenectomy in managing these anemias, considering both benefits and risks.

Main Methods:

  • Literature review of molecular studies, clinical heterogeneity, and treatment outcomes.
  • Analysis of current management guidelines regarding splenectomy for erythrocyte membrane disorders.

Related Experiment Videos

Main Results:

  • Significant genetic heterogeneity exists, particularly in spherocytosis, with private mutations per kindred.
  • Splenectomy, especially laparoscopic, is a curative treatment for many, but carries long-term risks.
  • Risks include cardiovascular disease, thrombotic disorders, pulmonary hypertension, and overwhelming postsplenectomy infection.

Conclusions:

  • Splenectomy remains a key treatment but requires careful reevaluation due to potential long-term complications.
  • Updated management guidelines emphasize detailed discussion between healthcare providers, patients, and families regarding splenectomy considerations.